Next-Generation Sequencing
Flexible, high-throughput sequencing across platforms:
- Illumina: NovaSeq X, NovaSeq 6000, NextSeq 500/550, MiSeq
- Thermo Fisher: Ion Torrent Genexus, PGM Dx and Ion S5 Prime
Comprehensive Genomic Profiling
- Identify rare variants down to 3% allele frequencies - lower option for exploratory studies
- Validated in-house NGS assays for solid tumors and hematologic malignancies supporting clinical trials and translational research
- Validated data analysis pipelines for DNA and RNA variant detection, tumor fraction estimation, clonality and resistance tracking, longitudinal monitoring, visualization, or custom analyses
Neo RaDaR® ST for Pharma Partners
Unlock the power of tumor-informed MRD detection with the RaDaR ST assay, delivering real-time molecular insights and high-sensitivity ctDNA analysis to identify residual disease with confidence.
- Track tumor dynamics in real time
- Design smarter, more adaptive clinical trials
- Accelerate real-world impact across oncology pipelines
Learn more about the RaDaR ST assay and how it's redefining MRD-driven decision-making
TSO 500 Portfolio
TSO 500 HT Tissue and TSO 500 ctDNA v2 for broad genomic profiling to support patient enrollment, stratification, and exploratory analysis.
Learn more about TSO 500 solution for genomic profiling
We also offers RareCyte® liquid biopsy service.
Click images to enlarge
Exploratory NGS
Suite of NGS-validated assays for exploratory and research purposes with full bioinformatics support for comprehensive analysis. Includes customizable workflow options such as increased coverage to enhance sensitivity.
- Whole Genome Sequencing (WGS)
- Whole Exome Sequencing (WES)
- Whole Transcriptome Sequencing (WTS)
- RNA Exome Sequencing